Q2 2015 13F Holders as of 6/30/2015
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
108M
-
Number of holders
-
92
-
Total shares
-
18.1M
-
Shares change
-
+1.02M
-
Total reported value, excl. options
-
$577M
-
Value change
-
+$34.6M
-
Put/Call ratio
-
0.54
-
Number of buys
-
60
-
Number of sells
-
-25
-
Price
-
$31.95
Significant Holders of Intra-Cellular Therapies, Inc. - COMMON STOCK (ITCI) as of Q2 2015
94 filings reported holding ITCI - Intra-Cellular Therapies, Inc. - COMMON STOCK as of Q2 2015.
Intra-Cellular Therapies, Inc. - COMMON STOCK (ITCI) has 92 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 18.1M shares
of 108M outstanding shares and own 16.77% of the company stock.
Largest 10 shareholders include FMR LLC (5.25M shares), WASATCH ADVISORS INC (1.13M shares), Visium Asset Management, LP (1.05M shares), BlackRock Fund Advisors (992K shares), VANGUARD GROUP INC (724K shares), BlackRock Advisors LLC (711K shares), ADAGE CAPITAL PARTNERS GP LLC (700K shares), Redmile Group, LLC (610K shares), BlackRock Institutional Trust Company, N.A. (516K shares), and MILLENNIUM MANAGEMENT LLC (493K shares).
This table shows the top 92 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.